An observational study, following a trial, to assess the immunogenicity and safety of standard dose versus fractional doses of COVID-19 vaccines (Pfizer-BioNTech or AstraZeneca) or standard dose Coronavac given as an additional dose after priming with Coronavac or AstraZeneca in healthy adults in Indonesia
Outcome
To assess and compare the immune response over 12 months, measured as binding antibodies (IgG CMIA) following fractional versus standard doses of Pfizer or AstraZeneca or standard dose CoronaVac, given as a single additional dose in adults aged 18 years or more in Indonesia primed through
Sponsor
Murdoch Children's Research Institute
Date
-
Subjects
647 subjects